Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents


1. Aramine
2. Araminol
3. Bitartrate, Metaraminol
4. Hydroxyphenylpropanolamine
5. Isophenylephrine
6. M Hydroxynorephedrine
7. M Hydroxyphenylpropanolamine
8. M-hydroxynorephedrine
9. M-hydroxyphenylpropanolamine
10. Meta Hydroxynorephedrine
11. Meta-hydroxynorephedrine
12. Metaradrin
13. Metaraminol
14. Metaraminol Bitartrate (1:1)
15. Metaraminol Tartrate
16. Tartrate, Metaraminol
1. 33402-03-8
2. Metaraminol Tartrate
3. Metaraminol (+)-bitartrate Salt
4. Metaraminol (tartrate)
5. (-)-metaraminol Bitartrate
6. Metaradrine Tartrate
7. Zc4202m9p3
8. Nsc-758425
9. Araminum
10. Benzenemethanol, A-[(1s)-1-aminoethyl]-3-hydroxy-, (ar)-,(2r,3r)-2,3-dihydroxybutanedioate (1:1) (salt)
11. Levicor
12. Metaramin
13. Levicor Ampullen
14. Araminum Ampullen
15. 3-[(1r,2s)-2-amino-1-hydroxypropyl]phenol;(2r,3r)-2,3-dihydroxybutanedioic Acid
16. L-metraminol Bitartrate
17. Metaradrine Bitartrate
18. Aramine (sympathominetic)
19. Metaraminol Tartrate (1:1)
20. Unii-zc4202m9p3
21. Ims Metaraminol Bitartrat Ampullen
22. Metaraminol (r,r)-hydrogentartrat
23. Metaraminol Bitartrate [usp:jan]
24. Aramine (tn)
25. Einecs 251-502-3
26. Metaraminol Bitatrate
27. Prestwick3_000197
28. Metaraminol Bitartrate Salt
29. (-)-m-hydroxyphenylpropanolamine Bitartrate Salt
30. Schembl40982
31. Bspbio_000153
32. Bspbio_003506
33. Bpbio1_000169
34. 1-alpha-(1-aminoethyl)-m-hydroxybenzyl Alcohol Bitartrate
35. (-)-alpha-(1-aminoethyl)-m-hydroxybenzyl Alcohol Bitartrate
36. Hms2093a03
37. Hms3885j21
38. L-1-(m-hydroxyphenyl)-2-amino-1-propanol-d-hydrogen Tartrate
39. Metaraminol Bitartrate (jan/usp)
40. Pharmakon1600-01503251
41. Metaraminol Bitartrate [mi]
42. Ex-a1348
43. Hy-b1116
44. Metaraminol Bitartrate [jan]
45. 1-alpha-(1-aminoethyl)-m-hydroxybenzyl Alcohol Hydrogen D-tartrate
46. Metaraminol Tartrate [mart.]
47. Nsc758425
48. Metaraminol Bitartrate [vandf]
49. Metaraminol Tartrate [who-dd]
50. (-)-alpha-(1-aminoethyl)-m-hydroxybenzyl Alcohol Tartrate (1:1) (salt)
51. Akos037515726
52. Ccg-213141
53. Cs-4715
54. Metaraminol Bitartrate [usp-rs]
55. Nsc 758425
56. Benzyl Alcohol, Alpha-(1-aminoethyl)-m-hydroxy-, (-)-, Tartrate (1:1) (salt)
57. Ac-33541
58. Benzenemethanol, Alpha-(1-aminoethyl)-3-hydroxy-, (r-(r*,s*))-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1) (salt)
59. Bm166414
60. Metaraminol Bitartrate [orange Book]
61. Metaraminol Bitartrate (hydrogen L-tartrate)
62. Metaraminol Bitartrate [usp Impurity]
63. Metaraminol Bitartrate [usp Monograph]
64. D01019
65. F18205
66. Metaraminol Bitartrate, (r-(r*,s*))-
67. 402m038
68. Sr-05000001611
69. J-019180
70. Sr-05000001611-1
71. Q27107333
72. Metaraminol Bitartrate, United States Pharmacopeia (usp) Reference Standard
73. (-)-.alpha.-(1-aminoethyl)-m-hydroxybenzyl Alcohol Tartrate (1:1) (salt)
74. 3-((1r,2s)-2-amino-1-hydroxypropyl)phenol (2r,3r)-2,3-dihydroxysuccinate
75. Benzyl Alcohol, Alpha-(1-aminoethyl)-m-hydroxy-, Tartrate (1:1), D-(-)-
76. Benzenemethanol, Alpha-((1s)-1-aminoethyl)-3-hydroxy-, (alphar)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1)
1. (-)-metaraminol
2. Hydroxynorephedrine
3. L-metaraminol
4. Metaradrine
5. M-hydroxypropadrine
6. Pressonex
7. Metaraminol
| Molecular Weight | 317.29 g/mol |
|---|---|
| Molecular Formula | C13H19NO8 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 317.11106656 g/mol |
| Monoisotopic Mass | 317.11106656 g/mol |
| Topological Polar Surface Area | 182 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 274 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Metaraminol bitartrate |
| Active Ingredient | Metaraminol bitartrate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 10mg base/ml |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 2 of 2 | |
|---|---|
| Drug Name | Metaraminol bitartrate |
| Active Ingredient | Metaraminol bitartrate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 10mg base/ml |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
Sympathomimetics
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)
Vasoconstrictor Agents
Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)
Adrenergic alpha-1 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Agonists.)
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
49
PharmaCompass offers a list of Metaraminol Bitartrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Metaraminol Bitartrate manufacturer or Metaraminol Bitartrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Metaraminol Bitartrate manufacturer or Metaraminol Bitartrate supplier.
A Aramine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aramine, including repackagers and relabelers. The FDA regulates Aramine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aramine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Aramine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Aramine supplier is an individual or a company that provides Aramine active pharmaceutical ingredient (API) or Aramine finished formulations upon request. The Aramine suppliers may include Aramine API manufacturers, exporters, distributors and traders.
click here to find a list of Aramine suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Aramine DMF (Drug Master File) is a document detailing the whole manufacturing process of Aramine active pharmaceutical ingredient (API) in detail. Different forms of Aramine DMFs exist exist since differing nations have different regulations, such as Aramine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Aramine DMF submitted to regulatory agencies in the US is known as a USDMF. Aramine USDMF includes data on Aramine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Aramine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Aramine suppliers with USDMF on PharmaCompass.
A Aramine written confirmation (Aramine WC) is an official document issued by a regulatory agency to a Aramine manufacturer, verifying that the manufacturing facility of a Aramine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Aramine APIs or Aramine finished pharmaceutical products to another nation, regulatory agencies frequently require a Aramine WC (written confirmation) as part of the regulatory process.
click here to find a list of Aramine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Aramine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Aramine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Aramine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Aramine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Aramine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Aramine suppliers with NDC on PharmaCompass.
Aramine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aramine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Aramine GMP manufacturer or Aramine GMP API supplier for your needs.
A Aramine CoA (Certificate of Analysis) is a formal document that attests to Aramine's compliance with Aramine specifications and serves as a tool for batch-level quality control.
Aramine CoA mostly includes findings from lab analyses of a specific batch. For each Aramine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aramine may be tested according to a variety of international standards, such as European Pharmacopoeia (Aramine EP), Aramine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aramine USP).